Printer Friendly

Articles from M2 Pharma (January 29, 2019)

1-12 out of 12 article(s)
Title Author Type Words
AbbVie wins US FDA's approval for IMBRUVICA & obinutuzumab combination for adult patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. 293
Biovitrum acquires United States rights to Synagis from AstraZeneca. 174
CStone Pharmaceuticals receives National Medical Products Administration approval for of BLU-554 Phase I clinical trial in China. 180
CStone wins CTA's approval in China to begin Phase I trial for FGFR4 inhibitor BLU-554 (CS3008). 258
EMMAC Life Sciences closes acquisition of Swiss wellness CBD company, Blossom. 198
Innovent Biologics Inc submits NDA for biosimilar product candidate of bevacizumab with the NMPA for multiple types of malignant tumors. 282
Medicure to market ReDS Device for congestive heart failure patients in the US through its existing commercial organisation. 243
NextPharma agrees to purchase Santen's Tampere manufacturing facility and associated operations. 143
Orion Oyj signs EUR100m loan agreement with European Investment Bank in Espoo. 134
Ortho Clinical Diagnostics promotes Robert Yates to chairman & CEO. 164
Thermo Fisher Scientific to dispose USD1.14bn Anatomical Pathology business in Q2 2019. 169
Xyntek names new senior director. 200

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters